Navigation Links
Combo Therapy Helps Multiple Myeloma Patients
Date:12/12/2008

Three-quarters of those who had relapsed saw disease stabilize or improve, study shows

FRIDAY, Dec. 12 (HealthDay News) -- A new combination of medicines designed to boost immune function can help some multiple myeloma patients, according to interim results from an ongoing Mayo Clinic study.

The researchers found that combining a new immunomodulatory drug called pomalidomide with dexamethasone (pom/dex) improved or stabilized disease in 76 percent of multiple myeloma patients who'd relapsed after previous treatment.

Multiple myeloma, a cancer that begins in white blood cells called plasma cells, affects about three in 100,000 people per year. There is no cure, but the disease can be managed. Immunomodulatory drugs interfere with cancer cell growth and stimulate the immune system to attack cancer cells.

The Mayo study began in November 2007 and has enrolled 60 patients, who took 2 milligrams of pomalidomide orally a day for a 28-day cycle and 40 mg of dexamethasone orally on days 1, 8, 15 and 22. They also took 325 mg of aspirin daily to prevent blood clots, a potential problem for patients taking immunomodulatory drugs.

Of the 60 patients, 58 percent have responded to therapy with at least a 50 percent decrease in detectable tumor burden as measured by blood protein levels, a marker for myeloma. This includes one patient who achieved complete remission, 14 patients who achieved at least a 90 percent decrease in blood proteins and 11 patients who remained stable.

"These are high remission rates, and they happened quickly," lead researcher and hematologist Dr. Martha Lacy said in a Mayo news release.

Side effects included anemia and declines in blood counts. In most patients, these side effects were mild.

Pomalidomide, also called CC-4047, belongs to the same class of immunomodulatory drugs as thalidomide and lenalidomide, both of which have been approved by the U.S. Food and Drug Administration for use with dexamethasone for multiple myeloma patients who've had previous treatment.

The Mayo researchers found that pom/dex was helpful in 29 percent of patients who didn't respond to lenalidomide.

The interim results of the study, funded by Celgene, were presented at the annual meeting of the American Society of Hematology.

"We are excited about the potential of this drug combination to significantly help patients with myeloma. Based on these encouraging results, we are expanding the study to include other patient populations that may benefit from this therapy," Lacy said.

More information

The American Cancer Society has more about multiple myeloma.



-- Robert Preidt



Mayo Clinic, news release, Dec. 9, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Blood Pressure Pill Combo More Effective Than Diuretics
2. U.S. Cancer Rate-Death Rate Combo Drops for 1st Time
3. Combo Treatment Best for Anxiety Disorder in Kids
4. Vaginal/Caesarean combo delivery of twins safe, UT Southwestern-led research finds
5. Drug/radiation combo may help shrink established tumors
6. Inverness Medical Innovations Announces 4th Generation Rapid HIV Test - Determine(TM) HIV-1/2 Ag/Ab Combo
7. Once-Daily Combo Works for New HIV Patients
8. Two-Drug Combo Reduces Diabetic Kidney Damage
9. 3-Drug Combo Improves Advanced Pancreatic Cancer Outcomes
10. Combo Therapy Knocks Out Melanoma Tumors
11. Combo Kidney-Pancreas Transplant Boosts Survival in Diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Combo Therapy Helps Multiple Myeloma Patients
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, ... much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on ... week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held on April ... in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the ... lives with Parkinson’s disease and is the architect of this informative event to raise ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... President George H. Van Allen have signed a joint enrollment and degree completion ... seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The agreement ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... host, Swirl, A Wine Tasting Event at the La Gorce Country Club in ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Calif. , Feb. 5, 2016  Syneron ... global aesthetic device company, announced today that ... Candela North America, is scheduled to participate in ... Healthcare Conference on February 11, 2016 in ... will allow institutional investors to meet with the ...
(Date:2/5/2016)...  Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion ... Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction ... combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), ... Canada , Ireland ... the terms of the Agreement and Plan of Merger ...
(Date:2/5/2016)... --> --> ... the global active pharmaceuticals ingredients (APIs) market stood at ... US$185.9 bn by 2020. It is expected to expand ... The title of the report is "Active Pharmaceutical Ingredients ... by Therapeutic Area) - Global Industry Analysis, Size, Share, ...
Breaking Medicine Technology: